Matthew P. Goetz, MD, of the Mayo Clinic, reviews progress made during the past year on treatment of advanced disease.
Nikhil Wagle, MD, Dana-Farber Cancer Institute, discusses the genomic sequencing of ER-positive metastatic breast cancer that has become resistant to therapies and the implications for the choice of next therapy, clinical trial eligibility, and novel drug targets (Abstract S1-01).
Lisa A. Carey, MD, of the University of North Carolina, discusses a session she moderated on key data presented at SABCS, and gives her expert views on putting the research data into clinical practice.
Sabine Linn, MD, PhD, and Sonja Vliek, MD, both of the Netherlands Cancer Institute, discuss study findings on adjuvant ibandronate in postmenopausal women with early breast cancer (Abstract S6-02).
Eric P. Winer, MD, of the Dana-Farber Cancer Institute, summarizes his McGuire lecture on the past and future of breast cancer treatment.
Diana M. Eccles, MD, of the University of Southampton, discusses findings from a study of sporadic and hereditary breast cancer and whether BRCA status affects outcome in young breast cancer patients (Abstract S2-03).
